Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...
New research reveals a strong link between eye health and overall well-being and if you take regular eye check ups, it can ...
Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
Your eyes—retinal blood vessels and retinal imaging—may help predict heart disease, according to a new study. Here, doctors ...
FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...
Treatment with high dose aflibercept 8 mg can lead to similar visual outcomes with fewer injections for patients with RVO.
Retinal microvascular changes detected by OCT-A may provide details for earlier diagnosis of coronary artery stenosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback